Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
5.60
-0.21 (-3.61%)
At close: Mar 9, 2026, 4:00 PM EDT
5.67
+0.07 (1.25%)
After-hours: Mar 9, 2026, 4:51 PM EDT
Xeris Biopharma Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 291.85 | 203.07 | 163.91 | 110.25 | 49.59 | Upgrade
|
| Revenue Growth (YoY) | 43.72% | 23.89% | 48.68% | 122.32% | 142.67% | Upgrade
|
| Cost of Revenue | 42.57 | 36.83 | 28.65 | 22.63 | 13.32 | Upgrade
|
| Gross Profit | 249.28 | 166.24 | 135.27 | 87.61 | 36.27 | Upgrade
|
| Selling, General & Admin | 182.37 | 163.48 | 146.1 | 137.75 | 116.06 | Upgrade
|
| Research & Development | 31.17 | 25.56 | 22.34 | 20.97 | 25.16 | Upgrade
|
| Amortization of Goodwill & Intangibles | 10.84 | 10.84 | 10.84 | 10.84 | 0.55 | Upgrade
|
| Operating Expenses | 224.38 | 199.88 | 179.28 | 169.55 | 141.77 | Upgrade
|
| Operating Income | 24.9 | -33.65 | -44.01 | -81.94 | -105.5 | Upgrade
|
| Interest Expense | -29.08 | -30.49 | -26.61 | -14.1 | -7.18 | Upgrade
|
| Interest & Investment Income | 4.74 | 5.32 | 4.75 | 2.58 | 0.73 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 0.01 | 0 | 1.76 | -0.7 | Upgrade
|
| EBT Excluding Unusual Items | 0.55 | -58.8 | -65.87 | -91.7 | -112.66 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -9.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.41 | Upgrade
|
| Other Unusual Items | - | 1.7 | 2.36 | -4.38 | - | Upgrade
|
| Pretax Income | 0.55 | -57.1 | -63.5 | -96.08 | -122.73 | Upgrade
|
| Income Tax Expense | - | -2.27 | -1.25 | -1.42 | - | Upgrade
|
| Net Income | 0.55 | -54.84 | -62.26 | -94.66 | -122.73 | Upgrade
|
| Net Income to Common | 0.55 | -54.84 | -62.26 | -94.66 | -122.73 | Upgrade
|
| Shares Outstanding (Basic) | 160 | 147 | 138 | 136 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 173 | 147 | 138 | 136 | 79 | Upgrade
|
| Shares Change (YoY) | 17.69% | 6.61% | 1.51% | 71.62% | 85.32% | Upgrade
|
| EPS (Basic) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | Upgrade
|
| EPS (Diluted) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | Upgrade
|
| Free Cash Flow | 27.93 | -37.85 | -49.29 | -103.42 | -96.62 | Upgrade
|
| Free Cash Flow Per Share | 0.16 | -0.26 | -0.36 | -0.76 | -1.22 | Upgrade
|
| Gross Margin | 85.41% | 81.86% | 82.52% | 79.47% | 73.14% | Upgrade
|
| Operating Margin | 8.53% | -16.57% | -26.85% | -74.32% | -212.74% | Upgrade
|
| Profit Margin | 0.19% | -27.00% | -37.98% | -85.86% | -247.48% | Upgrade
|
| Free Cash Flow Margin | 9.57% | -18.64% | -30.07% | -93.80% | -194.84% | Upgrade
|
| EBITDA | 37.05 | -21.58 | -31.68 | -69.7 | -103.62 | Upgrade
|
| EBITDA Margin | 12.70% | -10.63% | -19.33% | -63.22% | -208.95% | Upgrade
|
| D&A For EBITDA | 12.16 | 12.07 | 12.33 | 12.24 | 1.88 | Upgrade
|
| EBIT | 24.9 | -33.65 | -44.01 | -81.94 | -105.5 | Upgrade
|
| EBIT Margin | 8.53% | -16.57% | -26.85% | -74.32% | -212.74% | Upgrade
|
| Revenue as Reported | 291.85 | 203.07 | 163.91 | 110.25 | 49.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.